Back to results
US 11,447,561 B2Granted
PD-L1 antibodies binding canine PD-L1
AssigneeIntervet Inc.
InventorsMohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
Life of this patent
Estimating the term…
Abstract
The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
Claims12
An isolated antibody or antigen binding fragment thereof that binds canine Programmed Death Ligand 1 (canine PD-L1) comprising
- (a) a CDRL1 that comprises the amino acid sequence of SEQ ID NO:
- 22;
- (b) a CDRL2 that comprises the amino acid sequence of SEQ ID NO:
- 23;
- (c) a CDRL3 that comprises the amino acid sequence of SEQ ID NO:
- 24;
- (d) a CDRH1 that comprises the amino acid sequence of SEQ ID NO:
- 19;
- (e) a CDRH2 that comprises the amino acid sequence of SEQ ID NO:
- 20;
- and
- (f) a CDRH3 that comprises the amino acid sequence of SEQ ID NO:
- 21;
- wherein the antibody and antigen binding fragment thereof bind canine PD-L1 and block the binding of canine PD-L1 to canine Programmed Death 1 (PD-1).
11 more elements
Dependencies are inferred from the claim text.